gip glp 1 dual agonist The Sustained Effects of a GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes: Cell Metabolism Dual GLP-1/GIP receptor agonists mechanism
Description
GLP-1s for Cancer Prevention Because population studies are observational, they cant prove that GLP-1s lower cancer risk
[DOI] [PMC free article] [PubMed] [Google Scholar] 212.Sathananthan A., Man C.D., Micheletto F., Zinsmeister A.R., Camilleri M., Giesler P.D
It has become one of the most prescribed weight loss medications in the world, and the comparison between semaglutide and tirzepatide is one of the most searched topics in the GLP-1 space
JACC 2020
But there are also some not-so-great changes like nausea
There is also a current clinical study examining injectable semaglutides effect on coronary atherosclerosis development [27]
